^
    Back
    Association details:
    Biomarker:PLK1 overexpression
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    SABCS 2020
    Title:

    Plk1 expression & efficacy of palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03)

    Published date:
    11/17/2020
    Excerpt:
    In the whole cohort, pts with high levels (> median) of PLK1 (PLK1-high) treated with PAL, had a worse PFS in a multivariate model (5.7 months (m) vs 9.3 m of median PFS in PLK1-High vs -Low;